drugset / Trial / NCT05686616
SGLT2 Inhibitor for Severe Tricuspid Regurgitation
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study to identify the efficacy of sodium glucose cotransporter 2 inhibitors add-on treatment on right ventricular remodeling and the amount of severe tricuspid regurgitation (TR) in patients with isolated severe TR.
Timeline
- Start
- 2022-04-13
- Primary completion
- 2024-04-13
- Completion
- 2025-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin Propanediol Hydrate | Unknown | 12.3 mg | — |